Literature DB >> 18543035

Review of fecal biomarkers in inflammatory bowel disease.

Andrew D Sutherland1, Richard B Gearry, Frank A Frizelle.   

Abstract

PURPOSE: We reviewed potential fecal biomarkers of inflammatory bowel disease and assessed their utility in a range of clinical applications.
METHODS: A literature search using PubMed, MEDLINE, and Embase database was performed, locating all language articles on fecal biomarkers, including calprotectin and lactoferrin. The references of these papers were searched manually for further references.
RESULTS: A wide range of fecal biomarkers have been evaluated in the research setting. Only fecal calprotectin and lactoferrin have translated into useful clinical tools. These biomarkers have demonstrated high sensitivity for organic intestinal disease and good correlation with other measures of disease activity in inflammatory bowel disease.
CONCLUSIONS: Fecal calprotectin and lactoferrin are useful triage tools to differentiate organic intestinal disorders from functional disorders. They also have a role in monitoring inflammatory bowel disease activity and predicting relapse.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18543035     DOI: 10.1007/s10350-008-9310-8

Source DB:  PubMed          Journal:  Dis Colon Rectum        ISSN: 0012-3706            Impact factor:   4.585


  27 in total

1.  Fecal calprotectin and ulcerative colitis endoscopic activity index as indicators of mucosal healing in ulcerative colitis.

Authors:  Tarang Taghvaei; Iradj Maleki; Farshad Nagshvar; Hafez Fakheri; Vahid Hosseini; Seyed Mohammad Valizadeh; Hassan Neishaboori
Journal:  Intern Emerg Med       Date:  2014-11-04       Impact factor: 3.397

Review 2.  Diagnostic accuracy of fecal lactoferrin for inflammatory bowel disease: a meta-analysis.

Authors:  Yan Wang; Fengyan Pei; Xingjuan Wang; Zhiyu Sun; Chengjin Hu; Hengli Dou
Journal:  Int J Clin Exp Pathol       Date:  2015-10-01

3.  Protein biomarkers in exfoliated cells collected from the human rectal mucosa: implications for colorectal disease detection and monitoring.

Authors:  Neil Anderson; Ibnauf Suliman; Tatiana Bandaletova; Austin Obichere; Rupert Lywood; Alexandre Loktionov
Journal:  Int J Colorectal Dis       Date:  2011-06-23       Impact factor: 2.571

4.  Inter-alpha inhibitor protein level in neonates predicts necrotizing enterocolitis.

Authors:  Hala Chaaban; Michael Shin; Edward Sirya; Yow-Pin Lim; Michael Caplan; James F Padbury
Journal:  J Pediatr       Date:  2010-06-17       Impact factor: 4.406

5.  Moderate performance of serum S100A12, in distinguishing inflammatory bowel disease from irritable bowel syndrome.

Authors:  Anastassios C Manolakis; Andreas N Kapsoritakis; Panagiotis Georgoulias; Chara Tzavara; Varvara Valotassiou; Anastasia Kapsoritaki; Spyros P Potamianos
Journal:  BMC Gastroenterol       Date:  2010-10-14       Impact factor: 3.067

Review 6.  Diagnostic utility of faecal biomarkers in patients with irritable bowel syndrome.

Authors:  Jan Däbritz; Jason Musci; Dirk Foell
Journal:  World J Gastroenterol       Date:  2014-01-14       Impact factor: 5.742

7.  Cancer antigen 125 levels in inflammatory bowel diseases.

Authors:  Hilmi Ataseven; Zeynel Abidin Oztürk; Mehmet Arhan; Osman Yüksel; Seyfettin Köklü; Mehmet Ibiş; Omer Başar; Fatma Meriç Yilmaz; Ilhami Yüksel
Journal:  J Clin Lab Anal       Date:  2009       Impact factor: 2.352

8.  Characterization of relations among sleep, inflammation, and psychiatric dysfunction in depressed youth with Crohn disease.

Authors:  David Benhayon; Ada Youk; F Nicole McCarthy; Stephanie Davis; David J Keljo; Athos Bousvaros; Diane Fairclough; David Kupfer; Daniel J Buysse; Eva M Szigethy
Journal:  J Pediatr Gastroenterol Nutr       Date:  2013-09       Impact factor: 2.839

Review 9.  Faecal calprotectin: Management in inflammatory bowel disease.

Authors:  José Manuel Benítez; Valle García-Sánchez
Journal:  World J Gastrointest Pathophysiol       Date:  2015-11-15

10.  Neutrophil-lymphocyte ratio: a controversial marker in predicting Crohn's disease severity.

Authors:  Sheng-Qiang Gao; Li-Dong Huang; Rui-Jie Dai; Dong-Dong Chen; Wei-Jian Hu; Yun-Feng Shan
Journal:  Int J Clin Exp Pathol       Date:  2015-11-01
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.